Compare AESI & NVCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AESI | NVCR |
|---|---|---|
| Founded | 2017 | 2000 |
| Country | United States | Switzerland |
| Employees | N/A | N/A |
| Industry | Metal Fabrications | Medical/Dental Instruments |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.8B | 2.0B |
| IPO Year | 2023 | 2015 |
| Metric | AESI | NVCR |
|---|---|---|
| Price | $10.18 | $15.32 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 6 | 6 |
| Target Price | $13.17 | ★ $28.08 |
| AVG Volume (30 Days) | ★ 3.1M | 1.8M |
| Earning Date | 05-04-2026 | 04-30-2026 |
| Dividend Yield | ★ 2.91% | N/A |
| EPS Growth | N/A | ★ 21.79 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $1,095,310,000.00 | $655,353,000.00 |
| Revenue This Year | $2.71 | $7.72 |
| Revenue Next Year | $17.78 | $6.74 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | 3.73 | ★ 8.28 |
| 52 Week Low | $7.64 | $9.82 |
| 52 Week High | $20.13 | $21.45 |
| Indicator | AESI | NVCR |
|---|---|---|
| Relative Strength Index (RSI) | 27.81 | 45.40 |
| Support Level | $10.46 | $14.85 |
| Resistance Level | $10.69 | $15.46 |
| Average True Range (ATR) | 0.85 | 1.10 |
| MACD | -0.30 | -0.15 |
| Stochastic Oscillator | 9.19 | 6.09 |
Atlas Energy Solutions Inc is a provider of proppant and logistics services to the oil and natural gas industry within the Permian Basin of West Texas and New Mexico, the active oil and natural gas basin in North America. Proppant is necessary to facilitate the recovery of hydrocarbons from oil and natural gas wells. One hundred percent of its sand reserves are located in Winkler and Ward Counties, Texas, within the Permian Basin, and its operations consist of proppant production and processing facilities, including two facilities near Kermit, Texas, and a third facility near Monahans, Texas.
NovoCure Ltd is an oncology company with a proprietary platform technology in the United States. Its business involves the development, manufacture, and commercialization of Tumor Treating Fields (TTFields) devices, including Optune Gio and Optune Lua, for the treatment of solid tumor cancers. Its pipeline consists of Trident, Lunar-2, Panova-3, Metis, and other products and technologies for the treatment of Glioblastoma, Non-small cell lung cancer, and Pancreatic cancer. Geographically, the company derives the majority of its revenue from the United States and the rest from Germany, Japan, and other markets.